問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Koo Foundation Sun Yat-Sen Cancer Center (在職)

Division of Thoracic Medicine

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

陳鵬宇
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

41Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳鵬宇

List

54Cases

2016-07-28 - 2020-11-01

Phase III

A Phase 3, Multicenter, Multinational, Randomized, Open-Label, Parallel-Arm Study of Avelumab (MSB0010718C) Plus Best Supportive Care Versus Best Supportive Care Alone as a Maintenance Treatment in Patients with Locally Advanced or Metastatic Urothelial Cancer Whose Disease Did Not Progress After Completion of First-Line Platinum-Containing Chemotherapy

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Cancer

  • Test Drug

    Avelumab (MSB0010718C)

Participate Sites
6Sites

Terminated6Sites

2018-07-30 - 2022-08-13

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Not yet recruiting2Sites

Recruiting1Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2016-07-01 - 2019-12-24

Phase III

A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB (MSB0010718C) IN COMBINATION WITH AND/OR FOLLOWING CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED EPITHELIAL OVARIAN CANCER

  • Condition/Disease

    Epithelial Ovarian Cancer

  • Test Drug

    MSB0010718C 20mg/ml Solution for Infusion

Participate Sites
7Sites

Terminated7Sites

王鵬惠
Taipei Veterans General Hospital

Division of Obstetrics & Gynecology

2016-11-01 - 2019-07-31

Phase III

A Phase 3 Study of ADXS11-001 Administered Following Chemoradiation as Adjuvant Treatment for High Risk Locally Advanced Cervical Cancer: AIM2CERV

  • Condition/Disease

    High Risk Locally Advanced Cervical Cancer

  • Test Drug

    ADXS11-001

Participate Sites
6Sites

Terminated6Sites

張廷彰
Linkou Chang Gung Medical Foundation

Division of Obstetrics & Gynecology

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB